HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Yasui-Furukori, N. Articles by Tateishi, T. Search for Related Content PubMed PubMed Citation Articles by Yasui-Furukori, N. Articles by Tateishi, T. Social Bookmarking                   What's this?

Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes

From the Department of Clinical Pharmacology (Dr Yasui-Furukori, Dr Takahata, Dr Tateishi) and First Department of Internal Medicine (Dr Saito), Hirosaki University School of Medicine, Hirosaki, Japan, and the Department of Pharmacy, Hirosaki University Hospital, Japan (Dr Uno, Dr Sugawara).

Lansoprazole is a substrate of CYP2C19 and CYP3A4. The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes. Eighteen volunteers—of whom 6 were homozygous extensive metabolizers (EMs), 6 were heterozygous EMs, and 6 were poor metabolizers (PMs) for CYP2C19—received three 6-day courses of either daily 50 mg fluvoxamine or placebo in a randomized fashion with a single oral 60-mg dose of lansoprazole on day 6 in all cases. Plasma concentrations of lansoprazole and its metabolites, 5-hydroxylansoprazole and lansoprazole sulfone, were monitored up to 24 hours after the dosing. During placebo administration, there was a significant difference in the area under the plasma concentration-time curve from time 0 to infinity (AUC_0-) of lansoprazole between CYP2C19 genotypes. Fluvoxamine treatment increased AUC_0- of lansoprazole by 3.8-fold (P < .01) in homozygous EMs and by 2.5-fold (P < .05) in heterozygous EMs, whereas no difference in any pharmacokinetic parameters was found in PMs. There was a significant difference in the fluvoxamine-mediated percentage increase in the AUC_0- of lansoprazole between CYP2C19 genotypes. The present study indicates that there are significant drug interactions between lansoprazole and fluvoxamine in EMs. CYP2C19 is predominantly involved in lansoprazole metabolism in EMs.

Key Words: Lansoprazole • CYP2C19 • fluvoxamine • interaction

Address for reprints: Norio Yasui-Furukori, MD, PhD, Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki 036-8562, Japan.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. Kumar, R. C. Brundage, W. S. Oetting, I. E. Leppik, and T. S. Tracy Differential Genotype Dependent Inhibition of CYP2C9 in Humans Drug Metab. Dispos., July 1, 2008; 36(7): 1242 - 1248. [Abstract] [Full Text] [PDF]

				A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin Drug Metab. Dispos., October 1, 2007; 35(10): 1737 - 1743. [Abstract] [Full Text] [PDF]

				R. R Shah Pharmacogenetics in drug regulation: promise, potential and pitfalls Phil Trans R Soc B, August 29, 2005; 360(1460): 1617 - 1638. [Abstract] [Full Text] [PDF]

				T. Uno, N. Yasui-Furukori, T. Takahata, K. Sugawara, and T. Tateishi Lack of Significant Effect of Grapefruit Juice on the Pharmacokinetics of Lansoprazole and Its Metabolites in Subjects With Different CYP2C19 Genotypes J. Clin. Pharmacol., June 1, 2005; 45(6): 690 - 694. [Full Text]